;
Skip to main content
Home > Week in Review > Clinical Status

Chronological Index of : Clinical Status

 Current Issue
  • Linzess linaclotide: Phase III started

    Almirall S.A. (Madrid:ALM), Barcelona, Spain Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD), Cambridge, Mass. Actavis plc (NYSE:ACT), Dublin, Ireland Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan AstraZeneca plc (LSE:AZN…

    Published on 11/17/2014
  • LT-02: Phase III started

    Lipid Therapeutics GmbH, Heidelberg, Germany Dr. Falk Pharma GmbH, Freiburg, Germany Product: LT-02 Business: Autoimmune Molecular target: NA Description: Controlled-release formulation of phosphatidylcholine that …

    Published on 11/17/2014
  • Renevia: Pivotal trial started

    BioTime Inc. (NYSE-M:BTX), Alameda, Calif. Product: Renevia (formerly HyStem-Rx) Business: Transplant Molecular target: NA Description: Biocompatible, implantable hyaluronan and collagen-based hydrogel cell delivery …

    Published on 11/17/2014
  • Vatelizumab: Phase II started

    Glenmark Pharmaceuticals Ltd. (NSE:GLENMARK; BSE:532296), Mumbai, India Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Product: Vatelizumab (SAR339658, GBR 500) Business: Autoimmune Molecular target: Integrin alpha(2) (…

    Published on 11/17/2014
  • Amantadine: Phase III started

    Adamas Pharmaceuticals Inc. (NASDAQ:ADMS), Emeryville, Calif. Product: Amantadine (ADS-5102) Business: Neurology Molecular target: NA Description: Oral extended-release formulation of amantadine Indication: Treat …

    Published on 11/10/2014
  • Bronchitol Mannitol: Phase III started

    Pharmaxis Ltd. (ASX:PXS; Pink:PXSLY), Frenchs Forest, Australia Product: Bronchitol Mannitol Business: Pulmonary Molecular target: Not available Description: Formulation of mannitol in a dry powder inhaler system …

    Published on 11/10/2014
  • Calmangafodipir: Completed Phase IIb enrollment

    PledPharma AB (SSE:PLED), Stockholm, Sweden Product: Calmangafodipir (PledOx) Business: Hematology Molecular target: Superoxide dismutase 2 mitochondrial (SOD2) (MNSOD) Description: Pyridoxyl ethyldiamine (PLED) analog …

    Published on 11/10/2014
  • CGF166: Phase I/II started

    GenVec Inc. (NASDAQ:GNVC), Gaithersburg, Md. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Product: CGF166 Business: Other Molecular target: Atonal homolog 1 (ATOH1) (HATH1) Description: Atonal homolog 1 (ATOH1; …

    Published on 11/10/2014
  • CPX-351: Phase III complete enrollment

    Celator Pharmaceuticals Inc. (NASDAQ:CPXX), Ewing, N.J. Product: CPX-351 Business: Cancer Molecular target: DNA polymerase; Topoisomerase II (TOP2) Description: Liposomal formulation of cytarabine and daunorubicin …

    Published on 11/10/2014
  • Dex-IN: Phase II started

    Recro Pharma Inc. (NASDAQ:REPH), Malvern, Pa. Product: Dex-IN Business: Neurology Molecular target: Adrenergic receptor alpha 2 (ADRA2) Description: Intranasal formulation of dexmedetomidine, an adrenergic receptor …

    Published on 11/10/2014
  • Ebola tablet vaccine: Phase I start

    Vaxart Inc., San Francisco, Calif. Product: Ebola tablet vaccine Business: Infectious Molecular target: NA Description: Tablet vaccine containing an adenovirus serotype 5 (Ad5) vector encoding an Ebola antigen and a …

    Published on 11/10/2014
  • Epidiolex Cannabidiol: Phase II/III started

    GW Pharmaceuticals plc (LSE:GWP; NASDAQ:GWPH), Salisbury, U.K. Product: Epidiolex Cannabidiol Business: Neurology Molecular target: Cannabinoid receptors Description: Oral liquid formulation of cannabidiol, a …

    Published on 11/10/2014
  • GC021109: Phase Ia started

    GliaCure Inc., Boston, Mass. Tufts University, Medford, Mass. Product: GC021109 Business: Neurology Molecular target: NA Description: Small molecule that stimulates phagocytosis and anti-inflammatory to reduce pro-…

    Published on 11/10/2014
  • Ibudilast: Phase II started

    MediciNova Inc. (NASDAQ:MNOV; JASDAQ:4875), San Diego, Calif. Kyorin Pharmaceutical Co. Ltd. (Tokyo:4569), Tokyo, Japan Product: Ibudilast (MN-166/AV411) Business: Neurology Molecular target: Phosphodiesterase-4 (PDE-4…

    Published on 11/10/2014
  • Imetelstat: Phase II resumed

    Geron Corp. (NASDAQ:GERN), Menlo Park, Calif. Product: Imetelstat (GRN163L) Business: Cancer Molecular target: Telomerase Description: Oligonucleotide that competitively inhibits telomerase activity Indication: Treat …

    Published on 11/10/2014
  • Lucitanib: Phase II started

    Advenchen Laboratories LLC, Moorpark, Calif. Clovis Oncology Inc. (NASDAQ:CLVS), Boulder, Colo. Servier, Neuilly-sur-Seine, France Product: Lucitanib (AL3810, E-3810) Business: Cancer Molecular target: Fibroblast growth…

    Published on 11/10/2014
  • MBC-11: Phase I started

    MBC Pharma Inc., Aurora, Colo. Osteros Biomedica Ltd., Moscow, Russia Product: MBC-11 Business: Musculoskeletal Molecular target: NA Description: Synthetic chemical conjugate of etidronate, a bone-targeting vehicle, and…

    Published on 11/10/2014
  • Oral omecamtiv mecarbil: Phase II ongoing

    Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Cytokinetics Inc. (NASDAQ:CYTK), South San Francisco, Calif. Product: Oral omecamtiv mecarbil Business: Cardiovascular Molecular target: Cardiac myosin Description: …

    Published on 11/10/2014
  • Oral solithromycin: Completed Phase III enrollment

    Cempra Inc. (NASDAQ:CEMP), Chapel Hill, N.C. Cubist Pharmaceuticals Inc. (NASDAQ:CBST), Lexington, Mass. Toyama Chemical Co. Ltd., Tokyo, Japan Product: Oral solithromycin (CEM-101) (formerly OPT-1068) Business: …

    Published on 11/10/2014
  • STM 434: Phase I started

    Atara Biotherapeutics Inc. (NASDAQ:ATRA), Brisbane, Calif. Product: STM 434 Business: Cancer Molecular target: Activin A Description: Soluable activin receptor type 2B (ACVR2B)-Fc fusion protein that binds activin A …

    Published on 11/10/2014
  • VC-01: Phase I/II started

    ViaCyte Inc., San Diego, Calif. Product: VC-01 Business: Endocrine/Metabolic Molecular target: NA Description: PEC-01 cells, which are human embryonic stem cell (hESC)-derived pancreatic progenitor cells, encapsulated …

    Published on 11/10/2014
  • Adipose-derived stem and regenerative cells: Phase II action

    Cytori Therapeutics Inc. (NASDAQ:CYTX; Xetra:XMPA), San Diego, Calif. Product: Adipose-derived stem and regenerative cells (ADRCs) Business: Cardiovascular Molecular target: NA Description: Adipose-derived stem and …

    Published on 11/3/2014
  • AG-221: Phase I/II started

    Agios Pharmaceuticals Inc. (NASDAQ:AGIO), Cambridge, Mass. Celgene Corp. (NASDAQ:CELG), Summit, N.J. Product: AG-221 Business: Cancer Molecular target: Isocitrate dehydrogenase 2 (IDH2) Description: Inhibitor of mutated…

    Published on 11/3/2014
  • BTH1704: Phase Ib started

    Biothera Inc., Eagan, Minn. Product: BTH1704 Business: Cancer Molecular target: Mucin 1 (MUC1) (CD227) Description: mAb against mucin 1 (MUC1; CD227) Indication: Treat advanced pancreatic cancer Endpoint: Maximum …

    Published on 11/3/2014
  • CPI-613: Phase I started

    Cornerstone Pharmaceuticals Inc., Cranbury, N.J. Product: CPI-613 Business: Cancer Molecular target: Pyruvate dehydrogenase (PDH) Description: Analog of alpha-lipoic acid that targets the mitochondrial enzymes pyruvate …

    Published on 11/3/2014

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993